Mammary Cell News Volume 14.21 | Jun 2 2022

    By
    Bob
    -
    0
    77







    2022-06-02 | MCN 14.21


    Mammary Cell News by STEMCELL Technologies
    Vol. 14.21 – 2 June, 2022
    TOP STORY

    Cancer-Cell-Secreted Extracellular Vesicles Suppress Insulin Secretion through miR-122 to Impair Systemic Glucose Homeostasis and Contribute to Tumour Growth

    Investigators showed that breast cancer-derived extracellular vesicles suppressed pancreatic insulin secretion to impair glucose homeostasis.
    [Nature Cell Biology]

    AbstractPress Release
    Dr. Kristina McBurney and Leanna Bedell discuss how you can use social media to advance your scientific career. Watch now.
    PUBLICATIONSRanked by the impact factor of the journal

    STING Agonism Reprograms Tumor-Associated Macrophages and Overcomes Resistance to PARP Inhibition in BRCA1-Deficient Models of Breast Cancer

    Using a syngeneic genetically-engineered mouse model of breast tumor driven by Brca1 deficiency, researchers showed that tumor-associated macrophages blunted PARP inhibitors efficacy both in vivo and in vitro.
    [Nature Communications]

    Full Article

    YAP Inhibits ERα and ER+ Breast Cancer Growth by Disrupting a TEAD-ERα Signaling Axis

    Scientists uncovered the role of Hippo signaling and the tumor suppressor function of YAP in estrogen receptor positive (ER+) breast cancer.
    [Nature Communications]

    Full Article

    AMP-Activated Protein Kinase Promotes Breast Cancer Stemness and Drug Resistance

    The authors investigated the role of AMP-activated protein kinase in the maintenance of breast cancer stem cells state/function.
    [Disease Models & Mechanisms]

    Abstract

    Higher Efficacy of Resveratrol against Advanced Breast Cancer Organoids: A Comparison with That of Clinically Relevant Drugs

    Investigators used advanced breast cancers (ABCs)-derived organoids as the ex vivo therapeutic platform to clarify the effectiveness of resveratrol against different ABC subtypes.
    [Phytotherapy Research]

    Abstract

    COL8A1 Facilitates the Growth of Triple-Negative Breast Cancer via FAK/Src Activation

    Scientists investigated the biological function of COL8A1 on TNBC progression. The tumor growth and metastasis of TNBC cells were evaluated using three-dimensional culture methods and xenograft mouse models
    [Breast Cancer Research and Treatment]

    Abstract

    Breast Cancer-Stromal Interactions: Adipose-Derived Stromal/Stem Cell Age and Cancer Subtype Mediated Remodeling

    Conditioned media-based experiments showed that young adipose-derived stromal/stem cells donor age elevated endocrine response in ER-α+ breast cancer cell lines.
    [Stem Cells and Development]

    Abstract

    Live-Attenuated Poliovirus-Induced Extrinsic Apoptosis through Caspase 8 within Breast Cancer Cell Lines Expressing CD155

    Researchers investigated the oncolytic activity of live-attenuated poliovirus in breast cancer cell lines. The CD155 expression level in two human breast cancer cell lines and a normal breast cell line were evaluated using real-time PCR and flow cytometry.
    [Breast Cancer]

    Abstract

    REC8 Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells by Targeting CDC20

    The authors investigated the effects and underlying mechanism of REC8 on the proliferation, migration and invasion of breast cancer cells.
    [Molecular Medicine Reports]

    Abstract
    Register for a recorded organoid panel discussion moderated by Dr. James Wells
    REVIEWS

    Hippo Signaling Pathway: A Comprehensive Gene Expression Profile Analysis in Breast Cancer

    Investigators note the deregulation of several Hippo signaling elements in breast cancer patients. Moreover, they see examples of negative correlations between methylation of Hippo genes and mRNA expression.
    [Biomedicine & Pharmacotherapy]

    Full ArticleGraphical Abstract
    INDUSTRY AND POLICY NEWS

    New Phase Ib/II Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline Insulin Resistance

    SynDevRx, Inc. announced the opening of a first-of-its-kind Phase Ib/II study for patients with TNBC and baseline insulin resistance, testing the novel study drug evexomostat in combination with standard-of-care treatment Halaven®.
    [SynDevRx, Inc. (Business Wire, Inc.)]

    Press Release
    FEATURED EVENT

    The Australasian Society for Stem Cell Research (ASSCR) Annual Meeting

    November 16 – 18, 2022
    Melbourne, Victoria, Australia

    > See All Events

    JOB OPPORTUNITIES

    Staff Scientist – Breast Cancer Research Pathology

    Institute of Cancer Research – London, England, United Kingdom

    Analytical Scientist – Statistical Bioinformatics

    Institute of Cancer Research – London, England, United Kingdom

    Postdoctoral Associate – Cancer Biology and Metabolism

    Baylor College of Medicine – Houston, Texas, United States

    Postdoctoral Position – Breast Cancer Treatment Resistance

    Oslo University Hospital – Oslo, Norway

    Principal Investigator – Interdisciplinary Research in Biology

    CNRS – Paris, France

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter